Effects of GLP-1–Related Therapies on Lean Mass and Body Composition: A Narrative Review
Glucagon-like peptide-1 (GLP-1) receptor agonists (RAs) (GLP-1RAs) and incretin-based multiagonist therapies have become among the most widely prescribed medications for obesity and type 2 diabetes mellitus (T2DM) management, producing clinically meaningful reductions in body weight and fat mass (FM). Concerns have e...